French research institute initiates combination study of clevudine and viread for HBV

Published: 2008-07-14 06:01:00

Updated: 2008-07-14 06:01:00

Bukwang Pharm says the French National Agency for Research on AIDS and Viral Hepatitis (ANRS), with the support of Pharmasset, Inc. and Gilead Sciences, Inc. has initiated the first head-to-head study of clevudine and Viread (tenofovir disoproxil fumarate) administered separately, versus their co...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK